DalCor Pharmaceuticals

Executive Summary

DalCor Pharmaceuticals is a private biopharmaceutical company pioneering precision medicine for cardiovascular disease. Its lead asset, dalcetrapib, targets patients with the ADCY9 AA genotype, a genetic variant associated with higher risk of recurrent heart attacks. Dalcetrapib is a CETP inhibitor that previously showed a 50% reduction in cardiovascular events in AA genotype patients in a Phase 2b study. The company is currently conducting a confirmatory Phase 3 trial (NCT04861456) to validate these findings. If successful, dalcetrapib would be the first pharmacogenetic therapy for secondary prevention of cardiovascular events, addressing a significant unmet need in the estimated 20% of heart attack patients with the AA genotype. DalCor has raised substantial funding from investors including Medicxi, and is led by a management team with deep expertise in cardiovascular drug development. The confirmatory Phase 3 trial is fully enrolled with topline results expected in late 2026. Positive data would position DalCor for regulatory submission in the US and Europe, potentially leading to market approval in 2027-2028. The company's precision medicine approach de-risks the development pathway compared to traditional cardiovascular drugs, though Phase 3 carries inherent execution risk. DalCor's valuation will heavily depend on Phase 3 outcomes and potential partnership or acquisition interest from larger cardiovascular players.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data Readout45% success
• 2026FDA Breakthrough Therapy Designation30% success
• 2027Strategic Partnership or Licensing Deal25% success